Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-12

Clinical Trial Update: PLX3397 KIT in Acral aNd mucOsal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for PLX3397 (KIT inhibitor) in acral and mucosal melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PLX3397 (PLX3397)

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED